Tuberculosis: Back on the Immunologists' Agenda  by Kaufmann, Stefan H.E.
Immunity 24, 351–357, April 2006 ª2006 Elsevier Inc. DOI 10.1016/j.immuni.2006.04.003CommentaryTuberculosis: Back on
the Immunologists’ AgendaStefan H.E. Kaufmann1,*





Although tuberculosis research was instrumental in
the birth of immunology, the two disciplines soon sep-
arated. The time is ripe for a reunion. Immunology has
much to offer for rational intervention measures to-
ward tuberculosis control.
Introduction
At the end of the 19th century, 40%–50% of all deaths
in the working populations of major European cities
were caused by tuberculosis (Kaufmann and Winau, 2005).
It is no wonder that measures to reduce this burden
were considered of high importance, not only for health
but also for socioeconomic reasons. In this environ-
ment, Robert Koch embarked on elucidating the etiol-
ogy of tuberculosis and other infectious diseases and
laid the basis for the new discipline of medical microbi-
ology by formulating the general conceptual framework
and developing the necessary methodologies (Figure 1).
Soon thereafter, Koch accidentally stumbled upon the
yet-to-exist field of immunology during his attempt to
develop a vaccine against tuberculosis. He had de-
signed a subunit vaccine, which he claimed could cure
tuberculosis. This claim was enthusiastically received
all over the world (Figure 2). Yet, when this vaccine
was tested in a clinical trial, it soon turned out to be
Koch’s greatest failure. Nevertheless, he continued to
work on immune intervention for tuberculosis—in vain.
In contrast, his sanitary and hygienic measures, which
were based on the discovery of the infectious etiology
of the disease, had a significant impact on tuberculosis
control. Paul Ehrlich, Emil von Behring, the fathers of the
concept of acquired specific immunity, were introduced
to science through tuberculosis by Robert Koch. Simi-
larly, the father of the concept of innate immunity, Elie
Metchnikoff at the Pasteur Institute, had a genuine inter-
est in tuberculosis. Undoubtedly, the importance of
medical microbiology for society provided the bulk of
the financial resources for the birth of immunology for
Paul Ehrlich and Emil von Behring and Elie Metchnikoff.
Yet, the relationship between immunology and tubercu-
losis has been ambivalent from the outset.
The Protracted Divorce between Tuberculosis
and Immunology
The concept of specific acquired immunity was born
with the discovery by von Behring of passive transfer
of protection against the bacterial toxins diphtheria
and tetanus with serum antibodies. The failure to trans-
fer protection against tuberculosis with specific anti-
bodies at the beginning of the 20th century indicated
*Correspondence: kaufmann@mpiib-berlin.mpg.dethat there was something special in immunity to tuber-
culosis. This probably marks the beginning of the pro-
tracted divorce between tuberculosis research and
immunology. In the 19th century as well as today, tuber-
culosis research does not generate data rapidly be-
cause (1) the causative agent M. tuberculosis is an
extremely slow grower (w12 hr replication time as
compared to 30 min for most other bacteria); (2)
M. tuberculosis causes a chronic disease that often
breaks out after a long incubation time lasting for several
years or does not break out at all; (3) even a fully acti-
vated immune system fails to achieve sterile eradication,
and protection is reflected by containment of the patho-
gen and, consequently, measured in quantitative rather
than qualitative terms; and, finally, (4) M. tuberculosis is
an extremely hazardous pathogen requiring high safety
precautions. Thus, M. tuberculosis research is not the
model of choice for rapid data output and is one to avoid
when analyzing basic immunologic issues.
The development of a vaccine against tuberculosis by
Albert Calmette and Camille Gue´rin in 1921, an attenu-
ated Mycobacterium bovis strain, bacille Calmette-Gue´-
rin (BCG; Figure 1), and the discovery of the first antibi-
otic against tuberculosis, streptomycin by Selman
Waksman in 1943, soon led to the opinion that appropri-
ate control measures had become available for tubercu-
losis. Accordingly, only a few researchers in academia
considered tuberculosis of sufficient interest to do basic
research, notably George B. Mackaness, who uncov-
ered the intracellular lifestyle of M. tuberculosis and
the bicellular mechanism of protection comprising mac-
rophages and lymphocytes. With the assumption that
tuberculosis was controlled in ‘‘high-income’’ countries
by vaccination, chemotherapy, hygienic measures, and
improved living standards, research on tuberculosis
abated.
Reemergence of Tuberculosis as a Major
Health Threat
The emergence of AIDS, increasing incidences of multi-
drug-resistant (MDR) M. tuberculosis strains paralleled
by increasing migration between the continents and
the breakup of the Soviet Union, has brought tuberculo-
sis back to the public health agenda. The immunologic
weapon also proved to be blunt, because BCG fails to
protect against pulmonary tuberculosis in adults. To-
day, tuberculosis is recognized as one of the three major
microbial killers responsible for 8–9 million new cases
annually, of which 1.5–2.5 million die (Kaufmann and
McMichael, 2005).
Surveillance studies based on positive delayed-type
hypersensitivity (DTH) responses to purified protein de-
rivative (PPD) indicate that one third of the world popu-
lation is infected with M. tuberculosis, underlining that
our immune system is quite efficacious in containing
the pathogen but inefficacious in eradicating it. The
good news thereof is that infected individuals only
have a 10% lifetime risk of developing disease. The
bad news, however, is that a vast number of the world
population is at risk for reactivated tuberculosis once
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352Figure 1. Robert Koch’s and Albert Calm-
ette’s Legacy
Koch developed the methodologies required
for establishing medical microbiology as
a new scientific discipline. This includes spe-
cific staining methods for identification of
pathogens in affected tissue sites, micropho-
tography to allow verification of his obser-
vations made with the microscope, single
bacterial cell cultures on solid media, and ani-
mal experimentation to study the course of
disease. Koch could thus demonstrate that
a single bacterium causes a distinct type of
disease. Calmette followed Pasteur’s philos-
ophy that bacteria can be attenuated by serial
passage, e.g., in liquid medium. Hence, the
disease caused by members of one and
the same species could vary depending on the
degree of virulence. Highly attenuated strains
do not cause disease but still elicit protective
immunity. This is the basis for the develop-
ment of the live tuberculosis vaccine BCG.
Figure adapted from A. Calmette (1920), L’In-
fection bacillaire et al. tuberculose chez
l’homme et chez les animaux (Tubercle Bacil-
lus Infection and Tuberculosis in Man and An-
imals), Masson & Cie Editeurs Paris; G. Gaffky
et al. (1912) Robert Koch—Gesammelte
Werke (Vol. 1), Leipzig, Thieme.the immune system weakens. This is reflected by the
dangerous liaison between the human immunodefi-
ciency virus (HIV) and M. tuberculosis, because coinfec-
tion with both pathogens dramatically increases the risk
of developing tuberculosis. Similarly frightening is the
rapid emergence of MDR strains, notably of the geno-
type family Beijing/W, which is spreading globally (Glynn
et al., 2002). In 2005, more than 10% of all tuberculosis
cases in several countries were MDR, which is increas-
ing the cost for treatment by two orders of magnitude
or not permitting treatment options at all.
When the World Health Organization proclaimed a
global emergency for tuberculosis in 1993, tuberculosis
was included in the reports on major global health is-
sues. General agreement exists that both new drugs
and novel vaccines are urgently required for successful
control of this most threatening of all bacterial infec-
tions. Consequently, tuberculosis has gradually entered
the radar screens of major funding organizations includ-
ing National Institutes of Health (NIH), European Union
Framework Program 6 (EU FP6), and the Grand Chal-
lenges program of the Bill and Melinda Gates Founda-
tion. This provides a unique opportunity to exploit our
tremendously increased knowledge in basic immunobi-
ology and infection biology. High on the immunologists’
agenda of issues to be solved are (1) rational vaccination
regimes that protect when given preexposure and post-
exposure with M. tuberculosis, i.e., targeting not only
the naive population but also already infected individ-
uals; (2) exploitation of strategies to speed up clinical
vaccine trials based on better knowledge about bio-
markers reflecting pathologic, protective, or diseased
stages; and, perhaps most courageously, (3) designof immunologic intervention strategies for therapy of
tuberculosis patients and of vaccines that are oper-
ative in individuals coinfected with M. tuberculosis and
HIV.
The Biology of Tuberculosis
M. tuberculosis is a difficult-to-stain bacillus shielded by
a unique waxy cell wall composed of abundant glyco-
lipids, mycolic acids, peptidoglycans, and other carbo-
hydrate, lipid, and protein molecules (Boshoff and Barry,
2005). The genome of M. tuberculosis comprises ap-
proximately 4000 genes and recent studies have started
to analyze the gene expression profiles of M. tuberculo-
sis under different conditions such as starvation, dor-
mancy, and full-blown disease (Voskuil et al., 2003;
Cole et al., 1998; Rachman et al., 2006). These analyses
will help us to better understand activities of the patho-
gen during distinct stages of infection. Healthy individ-
uals with latent infection harbor dormant M. tuberculo-
sis. During latency, the microbe has low metabolism or
is nonactive and virtually fails to replicate. Genes con-
trolled by the DosR regulon are considered characteris-
tic of latent infection, although during latency not all
DosR regulated genes are upregulated, whereas some
non-DosR-regulated genes appear upregulated (Bosh-
off and Barry, 2005). Such dormancy proteins are inter-
esting candidates for postexposure vaccines. Disease
outbreak is preceded by high metabolic and replicative
activity of M. tuberculosis. Tentative evidence suggests
that reactivated mycobacteria can resuscitate neighbor-
ing microbes by producing resuscitation-promoting fac-
tors (Cohen-Gonsaud et al., 2005). Probably highly met-
abolically active bacteria are transmitted from host to
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353Figure 2. Enthusiasm about Robert Koch’s
Remedy for Tuberculosis in Scientific Ameri-
can, 1890
Word spread over the globe about Koch’s
claim to have developed a vaccine, and he
was hailed in scientific and lay publications
worldwide. His vaccine soon turned into a
complete failure after clinical trail data were
released. Figure adapted from Scientific
American, Vol. 23, December 6, 1890.host. These bacteria secrete numerous proteins into
their surroundings, which are considered candidate an-
tigens for preexposure vaccines.
In tuberculosis, the lung is typically the port of entry
and site of active disease although virtually all other or-
gans can be afflicted. During latency, M. tuberculosis is
contained in small productive granulomas where it re-
sides within macrophages (Kaufmann, 2005; Ulrichs
and Kaufmann, 2006). Although these lesions are visible
by X-ray, they normally do not affect the tissue apprecia-
bly and do not cause clinical signs of disease. During
reactivation, granulomas increase in size, and active
disease is characterized by caseous granulomas that
form cavities. Here, large amounts of bacteria (>1010 or-
ganisms) flourish extracellularly in the caseous detritus.
Soon after entry into the host lung, M. tuberculosis is
taken up by alveolar macrophages and dendritic cells
(DCs) (Kaufmann, 2005), which can then transport myco-
bacteria into draining lymph nodes and stimulate T cells.
Some mycobacteria are retained in the lung where inter-
actions between T cells and infected macrophages initi-
ate formation of a productive granuloma. M. tuberculo-
sis survives in macrophages by arresting phagosome
maturation at an early stage, thus preventing its destruc-
tion by reactive nitrogen and oxygen intermediates and
its degradation by lysosomal enzymes. Maintenance of
the granulomatous lesion is under the control of T lym-
phocytes and their mediators. Although CD4+ T lympho-cytes of Th1 type are critical for protective immunity, ev-
idence exists that CD8+ T cells as well as unconventional
T cells contribute to optimum protection (Kaufmann,
2005). The conventional CD4+ and CD8+ T cells recog-
nize mycobacterial peptides in the context of gene prod-
ucts of the major histocompatibility (MHC) class I or
class II molecules. Unconventional T cells comprise gd
T cells and CD1-restricted T cells with specificity for
nonproteinaceous antigens (Brigl and Brenner, 2004;
Kaufmann, 1996). Although the precise mechanisms of
antigen presentation in tuberculosis are incompletely
understood, recent evidence suggests a role of cross-
priming (Winau et al., 2006). Antibodies with specificity
for mycobacterial antigens are abundant in infected in-
dividuals. Yet, they are generally considered of no signif-
icant value for protective immunity against tuberculosis.
Aside from producing cytokines that activate macro-
phages and initiate granuloma formation, notably IFN-g
and tumor necrosis factor-a (TNF-a), T cells also ex-
press direct microbicidal activities via a concerted ac-
tion of perforins and granulysins (Kaufmann, 2005).
Mycobacteria-specific T cells also mediate DTH to PPD,
which can be elicited in apparently healthy individuals
years after original contact with M. tuberculosis, and
are generally considered to indicate latent infection.
During active tuberculosis, such DTH reactions as well
as peripheral blood T cell responses often disappear,
suggesting anergy.
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childhood tuberculosis. With more than 3 billion doses,
it is one of the most widely used vaccines globally and
has a remarkably good safety record. Yet, BCG is insuf-
ficient for control of adult tuberculosis (Kaufmann and
McMichael, 2005). Several, mostly speculative, explana-
tions have been brought forward for this failure. A widely
accepted explanation assumes that contact with atypi-
cal environmental mycobacteria stimulates an immune
response, which eradicates BCG prematurely and thus
curtails vaccine-induced protection (Andersen and Doh-
erty, 2005). This hypothesis implies that vaccine-induced
immunity depends on the persistence of BCG and wanes
after its eradication. The same argument can be made
against adult vaccination with recombinant vaccines
that are based on BCG. Another explanation assumes
that BCG is a potent inducer of CD4+ T cells, which are
largely responsible for granuloma formation and bacte-
rial containment, but is an insufficient stimulator of CD8+
T cells that are additionally required for long-term control
of the pathogen (Kaufmann and McMichael, 2005). Ac-
cordingly, BCG achieves early containment of M. tuber-
culosis in lesions and prevents severe tuberculosis but
fails to sustain long-term control, particularly once the
balance between pathogen persistence and host protec-
tion has been tipped in favor of M. tuberculosis.
New vaccine candidates follow a binary approach.
Proponents of subunit vaccines trust that few antigens
in an appropriate adjuvant or delivery system induce
sufficiently strong T cell responses, whereas propo-
nents of viable vaccines try to improve the currently
available BCG vaccine in an attempt to stimulate as
broad as possible an immune response against as
many as possible antigens. Many of these vaccines
stimulate different immune mechanisms and hence
may well be combined in a heterologous prime-boost
vaccination schedule.
Immunology Questions from Tuberculosis Research
What type of protection do we need; is it delay of dis-
ease reactivation, sterile eradication, or prevention of in-
fection? Generally, successful vaccines in use today
prevent manifestation of disease rather than prevent
infection. Yet, in most cases, the pathogen is ultimately
eradicated by the immune response restimulated by
natural infection with the pathogen. Moreover, currently
used vaccines benefit from antibodies rather than T
cells. Preexisting antibodies, which circulate in the
blood when the pathogen enters the host, neutralize, in-
activate, or opsonize infectious agents or their products,
thus reducing the pathogenic burden until the restimu-
lated memory immune response eradicates the patho-
gen. Protection induced by natural infection with M. tu-
berculosis with or without support by prior BCG
vaccination in early life apparently fails to eradicate the
pathogen and the disease that arises at a later time after
subtle changes in the immune response. Hence, it is
questionable whether a vaccine, which only delays dis-
ease reactivation but fails to achieve sterile eradication,
is sufficient, particularly with the current 15 million and
rising individuals coinfected with HIV and M. tuberculo-
sis (Kaufmann and McMichael, 2005).
Which cells and mechanisms would best be targeted
to achieve higher protection by better vaccines? The bi-cellular nature of immunity against tuberculosis defines
the main target cells for future vaccination strategies,
namely, different T cell populations as well as infected
macrophages and DCs. Previous tuberculosis vaccina-
tion strategies have largely focused on CD4+ T cells
(Kaufmann and McMichael, 2005; Andersen and Doh-
erty, 2005). However, different T cell populations likely
contribute to protection and, hence, measures to induce
an optimal combination of T cells could result in more ef-
ficacious protection such as through the use of appro-
priate adjuvants or carriers (McShane et al., 2004; Olsen
et al., 2001; Skeiky et al., 2004). A recombinant BCG
vaccine candidate with a deleted urease gene and
expressing listeriolysin from Listeria monocytogenes
induces better protection than wild-type BCG (Grode
et al., 2005). It is likely that this efficacy is due to cross-
priming, resulting in better T cell responses. Thus, if
crosspriming is essential for better protection against
tuberculosis, subunit vaccine candidates could be con-
structed to favor this process (Winau et al., 2006).
Generally, tuberculosis manifests itself in the lung
and, thus, recirculation of protective T cells to pulmo-
nary sites is a critical prerequisite for protection. Recent
evidence suggests that IL-17 and IL-23 are central to
lymphocyte migration to the lung (Kolls and Linden,
2004). Therefore, directing T lymphocytes to the lung,
for example, by activating the IL-17-producing Th17
cells, could improve the protective potential of novel
vaccine candidates. This is of particular importance for
subunit vaccine candidates.
Evidence is emerging that memory T cells participate
in protective immunity against tuberculosis. Moreover,
longevity of vaccine-induced protection is probably me-
diated by memory T cells (Lanzavecchia and Sallusto,
2005). Generation of memory T cells is promoted by
IL-7 and IL-15, and, hence, a means to stimulate these
cytokines by novel vaccine candidates should be ex-
ploited. Studies in several systems have indicated that
two types of memory T cells exist, namely, effector
memory and central memory T cells. Probably both
types of memory T cells are required for optimum pro-
tection, with effector memory T cells likely mediating ef-
fector functions in lesions and central memory T cells
connecting the regional immune response in pulmonary
lesions with that in lymphoid organs (van Panhuys et al.,
2005). Careful ex vivo and in situ analyses of cells in lung
lesions of tuberculosis patients could provide important
insights into the precise role of these memory T cells and
their functional relationship with each other and with ef-
fector T cells (Ulrichs and Kaufmann, 2006).
Reversal of immunosuppressive mechanisms may
also increase protective immunity. Recent interest has
focused on regulatory T cells (Belkaid and Rouse,
2005). It is generally assumed that regulatory T cells re-
duce the risk of immunopathology by suppressing on-
going immune response after pathogen eradication. In
tuberculosis, the immune system might be deceived
and generate regulatory T cells in the face of chronic
M. tuberculosis infection. An equally interesting alterna-
tive has been described recently in a viral model show-
ing that, during acute infection, effector T cells mature
into protective memory T cells after pathogen elimina-
tion (Barber et al., 2006). During chronic infection, effec-
tor T cells, however, become ‘‘exhausted’’ and hence fail
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inhibitory molecules of the CD28 family, seems to play
a critical role in exhaustion, because blocking of PD-1
interactions with its ligand PD-L1, a member of the B-7
family, relieves exhausted cells and allows their matura-
tion into memory T cells. It would be worthwhile to chal-
lenge the role of regulatory T cells and of exhausted T
cells in tuberculosis and determine the consequences
of their inhibition on reestablishing protective immu-
nity. Reversion of suppression or exhaustion is probably
achieved by immunomodulation independent from anti-
gen specificity, thus falling under the category of im-
mune intervention or generic vaccination.
A final means to increase protection against tubercu-
losis focuses on macrophages and DCs. It is well estab-
lished that chronically infected macrophages and prob-
ably DCs shut down numerous effector functions, and
recent experiments suggest direct interference with in-
tracellular signaling pathways in the host cell (Walburger
et al., 2004). Because protection is ultimately executed
by macrophages, it is likely that the most potent T cells
fail to fully activate effector functions in M. tuberculosis-
suppressed macrophages. Suppressed macrophage or
DC functions can be reestablished by drugs that modu-
late signaling pathways indicating a merger of drug and
vaccine development in tuberculosis (Walburger et al.,
2004).
There appears to be a frequent misconception in vac-
cinology that an inverse relationship exists between at-
tenuation and efficacy of viable vaccines. It is thought
that live vaccines represent a good compromise be-
tween sufficient attenuation to avoid side effects and
maintenance of satisfactory immunogenicity. This is not
corroborated by basic immunology. In fact, in many
systems, lower antigen doses provide stronger T cell im-
munity, whereas higher antigen load preferentially
results in humoral immunity. Consistent with this, a re-
combinant BCG strain that induces better protection is
more attenuated than the wild-type BCG (Grode et al.,
2005). Therefore, it is possible that persistent BCG acti-
vates suppressive immune mechanisms that downmo-
dulate vaccine-induced protection. To induce a more ef-
ficacious immune response comprising memory T cells
and active effector T cells and to avoid regulatory T cells
as well as T cell exhaustion, persistence of novel vac-
cines may need to be restricted. This could be accom-
plished by introducing auxotrophy or a suicide mecha-
nism by recombinant technology or by increasing
susceptibility to macrophage killing by conventional
attenuation.
An alternative to sterile eradication of M. tuberculosis
would be prevention of infection, which principally could
be best achieved by preexisting IgA antibodies and
highly active phagocytes in the lung that would rapidly
kill the few M. tuberculosis organisms in the alveolar
space after their inhalation (Neutra and Kozlowski,
2006). This is an attractive option because the burden
of the mycobacteria is small, but thus far there is insuf-
ficient evidence to favor direct bacterial killing of M. tu-
berculosis by preexisting antibodies and phagocytes.
What type of vaccine do we need: preexposure, post-
exposure, therapeutic? The large number of healthy but
infected individuals has already entered the first stage
toward disease development. It is likely that, in regionswith high tuberculosis incidences, virtually all adoles-
cents and adults are infected with M. tuberculosis and
therefore represent an important target population for
novel vaccines. BCG, as well as the second generation
of vaccine candidates that will enter phase II clinical
trials in the next few years, are preferentially designed
as preexposure vaccines. Can we develop both a preex-
posure and a postexposure vaccine? Can we rely on a
single vaccine, or do we need two different types of
vaccines? Can we even succeed with a therapeutic
vaccine, which creates a stronger immune response
on top of existing immunity, or should we target immu-
nomodulatory intervention strategies which, for exam-
ple, ablate suppressive immune mechanisms so that
protective immunity can be revitalized?
During latent infection, dormant M. tuberculosis is
likely to impair effector functions of infected macro-
phages and DCs, to exhaust effector T cells and to stim-
ulate regulatory T cells. As discussed above, therefore,
immunomodulatory interventions to reverse these fail-
ures deserve particular consideration for postexposure
vaccination of latently infected individuals and for thera-
peutic vaccination of patients with active disease. Two
additional features need to be considered in the context
of postexposure and therapeutic vaccination. First, met-
abolically active and dormant bacteria differ in their
gene expression profile, and hence different antigens
need to be selected for post- and preexposure vaccina-
tion (Kaufmann, 2005; Voskuil et al., 2003; Boshoff and
Barry, 2005). Early secreted antigens are considered
prime candidates for preexposure vaccines. However,
it appears that BCG fails to induce a considerable im-
mune response against DosR-regulated antigens.
Hence, a BCG-based recombinant postexposure vac-
cine may benefit from the introduction of DosR-regu-
lated antigens. Second, it is likely that dormantM. tuber-
culosis represent an undefeatable target for activated
macrophages and DCs due to their highly reduced me-
tabolism. One option to achieve killing of these patho-
gens would be to transform them from the dormant
into the metabolically active stage, for example, by
means of resuscitation-promoting factors that enzymat-
ically digest the cell wall and in this way signal a wake-up
call to dormant M. tuberculosis (Cohen-Gonsaud et al.,
2005). Obviously, this is a highly risky venture because
active M. tuberculosis can directly cause disease. Yet,
in experimental model systems, this might be an inter-
esting issue to analyze.
A combination of direct T cell stimulation and rever-
sion of suppression may provide the basis for novel in-
tervention strategies against tuberculosis. Ideally, this
combination would allow sterile eradication of the path-
ogen and, therefore, rescue infected individuals from the
risk of developing tuberculosis following HIV coinfec-
tion, because even profound T cell responses are ulti-
mately condemned to fail in controlling M. tuberculosis
in the face of CD4+ T cell depletion by HIV.
Are some infected individuals able to eradicate the
pathogen rather than contain it? Extensive epidemio-
logic surveillance studies based on a DTH response to
PPD indicate that 2 billion individuals worldwide have
had intensive contact with M. tuberculosis, thereby in-
ducing an antigen-specific T cell response. Further, ex-
perimental animals infected with M. tuberculosis rarely,
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matically increases the risk of rapidly developing active
tuberculosis. However, it is less clear whether credence
should be given to the far-reaching conclusion that one
third of the world’s population is latently infected with
M. tuberculosis. Increasing evidence from immunologi-
cal models suggests that memory T cells can persist in
the absence of the nominal antigen. If this holds true
for tuberculosis, a number of PPD+ individuals could
have developed an immune response strong enough
to eradicate the pathogen. Can we elucidate the respon-
sible immune response and, based on this knowledge,
define a vaccine that achieves sterile eradication of
M. tuberculosis? Thus far it is unclear how PPD+-infected
and PPD+-noninfected individuals can be distinguished.
Perhaps precise phenotyping and/or gene expression
profiling of different effector T cells, memory T cells,
and regulatory T cells will permit a distinction between
memory in the absence of, and memory sustained by,
M. tuberculosis. It is also possible that novel highly sen-
sitive noninvasive live imaging strategies will allow the
identification of a few dormant mycobacteria. However,
at this stage, this is pure speculation.
Can we shorten clinical vaccine trials with the help of
biomarkers? Despite the worrisome absolute numbers
of tuberculosis cases and deaths, incidences of tuber-
culosis rarely exceed 500 per 100,000 cases. Moreover,
clinical trials will probably exclude HIV-positive individ-
uals, and preexposure and postexposure vaccine trials
will exclude PPD+ or PPD2 vaccinees, respectively.
Well-defined high-risk groups are rarely available for
tuberculosis trials. As a corollary, large numbers of vac-
cinees need to be recruited for phase III trials. Further
complicating the matter, tuberculosis may not break
out even in infected individuals within a reasonable
time frame. It has been estimated that a phase III trial
for tuberculosis vaccines will last for at least 10–15 years
before statistical evaluation can be completed. Obvi-
ously, this raises the questions of whether clinical TB
vaccine trials can be shortened and whether a promising
vaccine candidate can be made available prior to trial
decoding. New vaccines against dual-use microorgan-
isms, such as anthrax, smallpox, or Ebola, cannot be
tested in clinical phase III trials, and, yet, it is possible
to license these vaccines for restricted use based on re-
liable correlates of protection in humans and protection
studies in relevant animal models rather than on definite
proof of vaccine efficacy in humans. Can we define bio-
markers for protection against tuberculosis that could
help speed up clinical vaccine trials?
Recent advances in global gene expression profiling
using peripheral blood cells as surrogate tissue have
led to the identification of biomarkers for predicting dis-
ease development, notably in cancer, or for monitoring
drug activity (Anderson and LaBaer, 2005; Hogrefe,
2005). In principle, biomarkers can provide valuable in-
sights into host defense against M. tuberculosis and
as a result of vaccination. This strategy should be pur-
sued for vaccine efficacy assessment in tuberculosis.
It is likely that a tailormade set of biomarkers can predict
the strength of the immune response against tubercu-
losis. Aside from the well-known and widely accepted
biomarker IFN-g produced by antigen-specific T cells
(Pai et al., 2004), other markers need to be considered,including cytokines, chemokines, and adhesion mole-
cules relevant to T cell, monocyte, and DC migration to
and granuloma formation in the lung, as well as markers
characteristic for protective T cells and for antimyco-
bacterial functions of macrophages and DCs. Nonimmu-
nologic mechanisms need to be considered as well.
Careful and unbiased analysis of global gene expression
profiles of cells from patients, healthy controls, HIV and
M. tuberculosis double-infected individuals, and BCG-
vaccinated newborns will guide the definition of a tailor-
made biosignature, which would be of great value for
predicting efficacy of novel vaccine candidates.
Concluding Remarks
Basic immunology has a lot to offer to rational vaccine
design against tuberculosis. What then can translational
research on tuberculosis pay back to basic immunol-
ogy? New insights into the long-lasting standoff be-
tween host and persistent infections, which have been
a driving force in the evolution of the immune system,
are likely to emerge. Precedents already exist demon-
strating that this long-term relationship hides numerous
mechanisms of greatest interest for immunobiology.
These include (1) unique mechanisms that allow M. tu-
berculosis to (mis)use macrophages and DCs as their
habitat by modifying the intracellular trafficking and sig-
naling machinery to their benefit (Boshoff and Barry,
2005), (2) unique antigenic repertoire of group I CD1-re-
stricted T cells specific for the most abundant cell-wall
glycolipds of mycobacteria (Brigl and Brenner, 2004),
and (3) discovery of gd T cells on the basis of their par-
ticular reactivity to mycobacterial components (Kauf-
mann, 1996). Numerous tantalizing questions can be ap-
proached by bringing together basic immunology and
translational research in tuberculosis, and solving these
questions will be rewarding to both areas of research.
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